Bayer Intellectual Property Gmbh

Basf Se Corporation

Basf Coatings Gmbh

Terranova Energy Gmbh

Schneider, Claudia

Claudia Schneider

Bernd Bruchmann

Ningshu Liu

Udo Nenner

Marc Buttmann

Anke KÜDDE

Bernhard Steinmetz

Andreas Decker

Erkan Yalcin

The present invention relates to: &#x2014;use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; &#x2014;combinations of a) said compound and b) one or more further active agents; &#x2014;a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; &#x2014;a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; &#x2014;use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and &#x2014;a method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN.

Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines

Growing community of inventors

Berlin, Germany

Claudia Schneider